Cantor Fitzgerald Maintains a 'Buy' on Galena Biopharma (GALE); A Name Still Worth Exploring

Cantor Fitzgerald maintains a 'Buy' on Galena Biopharma (NASDAQ: GALE) price target of $4.00.

Analyst, Mara Goldstein, said, "We are updating our financial model to reflect adjustments associated with the separation of RXi. Other than these adjustments, we are not changing our financial projections. Our 2012 EPS forecast is now ($0.99)...As with many other development-stage companies, the investment thesis is centered on product development, not earnings. Galena's NeuVax is currently being tested in a Phase III clinical trial, with sites in the U.S., Europe and Asia. The product, a therapeutic vaccine to prevent recurrence of breast cancer in women previously diagnosed with early stage cancer that have low-to-moderate levels of HER2 expression, represents a meaningful opportunity for the company."

For an analyst ratings summary and ratings history on Galena Biopharma click here. For more ratings news on Galena Biopharma click here.

Shares of Galena Biopharma closed at $1.52 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Bernstein SocGen Group Reiterates Outperform Rating on JD.com, Inc (JD), 'very cheaply valued'
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49